On April 18, 2026, President Trump signed an executive order directing federal agencies to "dramatically accelerate access" to psychedelic-based mental health treatments.

Six days later, the FDA acted on it.

According to the FDA's official press release dated April 24, 2026, the agency issued national priority vouchers to three companies:

• Compass Pathways — studying synthetic psilocybin for treatment-resistant depression
• Usona Institute — studying psilocybin for major depressive disorder
• Transcend Therapeutics — studying methylone (a compound similar to MDMA) for PTSD

The FDA also cleared DemeRx NB to begin a Phase I clinical study of noribogaine hydrochloride — a derivative of ibogaine — for alcohol use disorder. According to the FDA, this is the first time a U.S. clinical study of an ibogaine derivative has been greenlit.

What a "Priority Voucher" Actually Does

Speed is not the same as approval. The Usona Institute stated plainly that the voucher "accelerates FDA review to approximately one to two months" — but "does not alter scientific or regulatory standards."

These drugs are NOT approved. They are NOT legal to prescribe. The vouchers just mean the FDA has to look faster. The clinical trials still have to produce the data.

Compass Pathways CEO Kabir Nath said the company has "positive data from two large, well-controlled Phase 3 clinical trials," according to CNN's April 24 report by Jacqueline Howard and Ben Tinker. Phase 3 data and FDA approval are two different things.

The Executive Order: What's Real, What's Noise

Harvard Law's Petrie-Flom Center published a Q&A on April 18 with faculty director I. Glenn Cohen and senior fellow Mason Marks breaking down the order.

Cohen's assessment: much of what the EO does "solidifies the potential" for things already in motion — the Priority Review Voucher program existed before this order. He called it a "significant signal" more than a structural breakthrough.

Marks flagged one genuinely new provision: $50 million in federal matching funds for state psychedelic research programs. That number was almost certainly drafted in response to Texas, which allocated $50 million for publicly-funded ibogaine research after struggling to find a private institutional partner.

Fifty million dollars sounds substantial. In the context of FDA-sanctioned drug trials, Marks noted it "might not go very far" — but it could pull in private investment.

The order also instructs the FDA and DEA to build a pathway for eligible patients to access investigational psychedelics outside of formal trials. That's Right to Try territory. Real if it happens. Not guaranteed.

Who's Benefiting — And Why

FDA Commissioner Marty Makary specifically named veterans alongside the general population in his statement. HHS Secretary RFK Jr. echoed that, saying the administration is confronting "our nation's mental health crisis head-on, especially for our veterans."

That's not merely rhetoric. MDMA-assisted therapy for PTSD has shown real results in veteran populations. The ibogaine research that Texas funded was driven largely by evidence of its effectiveness in treating addiction among combat veterans.

Treatment-resistant depression affects roughly 30% of depression patients, according to widely cited clinical literature. Existing options — SSRIs, ECT, ketamine — don't work for everyone.

What Mainstream Coverage Is Getting Wrong

CNN's coverage was solid on the facts but framed this largely as a feel-good science story. Missing from their piece: any serious scrutiny of whether the FDA's bureaucratic structure can actually deliver on the speed being promised, or whether the DEA's parallel restrictions will undercut what the FDA is doing.

The DEA controls scheduling. Psilocybin is still Schedule I — meaning the DEA considers it to have NO accepted medical use and HIGH abuse potential. An FDA voucher doesn't change that classification overnight. Researchers still face enormous DEA paperwork and compliance burdens just to handle these substances legally.

Reason's Steven Greenhut correctly pointed out on April 24 that "real change will take more than an executive order" — and that the FDA's structural incentives still punish speed. As George Mason University economist Alex Tabarrok has argued, the FDA has every reason to delay: if it approves a bad drug, the casualties are visible. If it blocks a good drug for a decade, the people who died waiting are invisible.

That dynamic hasn't changed. A voucher doesn't rewrite FDA incentive structures.

The RFK Jr. Wrinkle

RFK Jr. is front and center in this announcement. He's also the same official overseeing an FDA that is — according to Reason's reporting — telling nursing homes not to serve Jell-O, banning flavored vaping products on one hand while loosening psychedelic restrictions on the other.

The inconsistency matters. A coherent health policy would ask: what's the actual standard for what the federal government restricts versus permits? Right now that standard is hard to identify.

What This Means

The FDA's April 24 actions are the most significant federal movement on psychedelic medicine in decades. The science behind psilocybin for depression and MDMA-like compounds for PTSD is legitimate — not fringe. Veterans and millions of Americans with treatment-resistant conditions deserve access to tools that might actually work.

But vouchers are NOT approvals. Fifty million dollars is NOT a revolution. And an executive order cannot, by itself, dismantle the DEA scheduling regime, rewrite FDA incentive structures, or guarantee that clinical trials produce the results researchers are hoping for.

This is a real first step. It is not the finish line.